BFRI - Biofrontera spikes after recruitment update on late-stage trial for skin cancer

Biofrontera (BFRI +17.7%) is trading sharply higher after announcing that the company enrolled 70% of patients in its Phase 3 study for Ameluz photodynamic therapy in superficial basal cell carcinoma ((sBCC)). The micro-cap biopharma company plans to recruit 186 patients across 12 U.S. study sites for the placebo-controlled study, which is designed to study Ameluz in combination with BF-RhodoLED lamp in sBCC, a major form of nonmelanoma skin cancer. The enrollment drive, which began in 2018, is expected to complete by the end of 2022. “Due to a demanding study protocol mandated by the FDA, the recruitment process has been taking a considerable amount of time and was additionally slowed down by the Covid pandemic, but has recently picked up again,” CEO Erica Monaco remarked. Early last month, Biofrontera (NASDAQ:BFRI) gained after announcing its preliminary financials for Q4 2021.

For further details see:

Biofrontera spikes after recruitment update on late-stage trial for skin cancer